The RYSE Golden Opportunities Fund offers the sharpest sector thesis on the Golden Visa route, digital health, and the lowest reported management fee in the segment at 0.5%. It also offers almost nothing to read: the manager publishes no fund page, no prospectus and no KID, so nearly every term below rests on a single directory profile or sponsored press coverage. That disclosure gap, not the strategy, is the fund's defining feature today, and it sets the agenda for any serious diligence.
Key takeaways
- A CMVM-regulated Portuguese venture fund for digital health, launched by London healthcare VC RYSE Asset Management as a reported joint venture with Portuguese manager FundBox.
- Headline term: a 0.5% annual management fee, marketed as the lowest among Portugal Golden Visa funds, with a reported but unconfirmed 20% performance fee.
- Reported €100,000 minimum and 96-month lock-up are single-source; fund size, term, custodian, auditor and inception date are all unpublished.
- The registry identifiers on record, CMVM 2434 and ISIN PTFXOPIM0009, have not been verified against the CMVM registry.
- US-investor policy is unknown, and there is no track record; RYSE's UK fund is a separate vehicle.
What does the fund invest in?
The mandate is the best-documented part of the story. This is venture capital dedicated to digital health: proven, revenue-generating HealthTech and MedTech companies with asset-light, scalable models that deliver measurable savings to healthcare systems. The scope runs across digital diagnostics, digital therapeutics, medical devices and data and discovery platforms, with named themes in women's health, mental health, cardiovascular and oncology. Investments go primarily into Portuguese companies, only after clinical validation or regulatory approval, with 3 to 7 year exit horizons per company.
Positioning-wise, it claims a genuine niche: the only Golden Visa fund dedicated to digital healthcare. Behind it is RYSE Asset Management, a London healthcare venture firm founded in 2017 whose partnership includes Shabir Chowdhary (finance and structuring), Dr John Lee Allen (healthcare) and Vivien de Tusch-Lec (strategy and growth). For Portugal, press coverage reports the CMVM-regulated vehicle was launched as a joint venture with Portuguese asset manager FundBox. RYSE's UK-based Special Opportunities Fund is a separate vehicle, so its record, whatever it is, does not belong to this fund. This one has no track record and no published portfolio: a blind pool with a well-articulated thesis.
What has the manager actually published?
Almost nothing, and this is the finding that organises everything else. As of July 2026, the RYSE website carries no dedicated fund page, no prospectus, no KID and no fund terms. Nomad Gate has no listing. What exists publicly is one directory profile, created in February 2026, and two press write-ups, one of them a sponsored feature.
That leaves the factsheet in an unusual state: the CMVM registration (reported as 2434), the ISIN (reported as PTFXOPIM0009), the €100,000 minimum, the 96-month lock-up and the 20% performance fee each trace back to a single source, unverified against the regulator or any fund document. Even basic facts are missing: no fund size, no target size, no inception date, no stated term, no custodian, no auditor, no NAV frequency. The Portuguese management entity of record has not been confirmed in documents either; the FundBox joint venture is reported by press. None of this means the terms are wrong. It means that, for now, they are claims.
What would the 0.5% fee actually cost you?
The management fee is the one commercial term with corroboration: 0.5% a year, reported by two independent write-ups and marketed as the lowest among Portugal Golden Visa funds. On a €500,000 Golden Visa subscription, assuming the rate applies to the full amount throughout, that is €2,500 a year:
| Holding period | Management fee at 0.5% p.a. |
|---|---|
| 6 years | €15,000 |
| 7 years | €17,500 |
| Full 96-month lock-up (8 years) | €20,000 |
Against the 1.5% to 2% typical of the route, the saving over an eight-year hold is substantial. But the back end is where a venture fund's economics live, and here the record splits: one directory reports a 20% performance fee while another source describes the performance fee as undisclosed, and no hurdle rate appears anywhere. Whether the carry applies from the first euro of gain or above a minimum return will matter far more to your net outcome than the headline fee. Treat the 0.5% as a genuine attraction and the rest of the fee schedule as unwritten until you have the offering documents.
How long is your money locked up?
The reported lock-up is 96 months, roughly eight years, with no published interim liquidity mechanism; the derived reading is that capital comes back at term as portfolio companies exit on their 3 to 7 year horizons. The fund's actual term, and any extension rights, are unpublished.
Mapped against the citizenship timeline, the shape is workable. Naturalisation realistically takes six years or more from application, and the €500,000 qualifying investment must remain in place throughout the residency process. An eight-year structure covers that window without forcing a mid-process reinvestment. The residual risks are the standard venture ones: exits can run late, extensions can stretch the tail, and early-stage healthcare outcomes are widely dispersed and not asset-backed. Nothing here is redeemable on demand, whatever the fee schedule saves you.
What should US citizens know?
Nothing has been published, which for a US person is itself the first data point. US-investor acceptance is recorded as unknown, there is no PFIC or QEF information, and no IRA route is described. As a non-US venture fund, this vehicle would generally be analysed as a PFIC for US taxpayers; without annual QEF information statements, the default PFIC regime taxes gains at top ordinary rates with an interest charge.
The sequence is therefore fixed: ask RYSE in writing whether US persons are accepted, whether the fund will provide annual PFIC/QEF information statements, and whether a self-directed IRA can subscribe. If the first answer is no, the analysis ends there. If the answers come back yes, model the position with a US tax adviser before subscribing. FATCA and foreign-asset reporting apply in any case.
How does it compare?
Within the funds database, this fund occupies a distinctive corner: the narrowest sector focus on the route, the lowest reported management fee, and among the thinnest public disclosure. Its natural comparators are the other healthcare-flavoured vehicles. The First Pharma Fund takes a private-equity approach to pharmaceutical assets, while the Prime Insight Fund backs healthcare and senior-care projects through a closed-end venture structure; each pairs the same demand thesis with a different risk shape. Comparing their published documents against RYSE's is instructive in both directions: it shows what disclosure is normal for the segment, and how much of it this fund has yet to match.
What to verify before wiring anything
No manager-published fund document was found for this fund: no fund page, prospectus, KID or terms sheet. Every headline figure, including the €100,000 minimum, the 96-month lock-up, the 20% performance fee, CMVM number 2434 and ISIN PTFXOPIM0009, rests on a single directory profile or press coverage. Subscribe only on the basis of the offering documents themselves, obtained directly from the manager, with the CMVM registration checked against the regulator's registry.
The concrete checklist, drawn from what the public record cannot answer. How much weight each item carries depends on your own situation and risk appetite:
- Identity. The CMVM registration (reported 2434) verified against the registry, the ISIN (reported PTFXOPIM0009), the exact legal form, and the Portuguese management entity of record behind the reported FundBox joint venture.
- Economics. The actual minimum (€100,000 reported by one directory, €500,000 quoted in press), the full fee schedule including the performance fee and any hurdle, and subscription or redemption fees.
- Structure and timeline. Fund size and target size, inception date, the fund term behind the 96-month lock-up, extension provisions, custodian, auditor and NAV frequency.
- US matters. US-person acceptance, QEF reporting and the IRA route, as above.
- Team. Which RYSE partners formally manage this Portuguese vehicle; the partnership listed publicly is RYSE's London team.
For an early-stage fund marketing privately, gaps like these are not unusual. They are still gaps, and the fund regulations are the only instrument that closes them.
Next step
If a focused digital-health thesis inside a Golden Visa wrapper appeals to you and the 0.5% fee survives contact with the full fee schedule, this fund is worth the document request. Roots can walk you through the offering documents and this checklist independently before you engage the manager, so the conversation starts from verified terms rather than marketing. This article is information, not investment, tax or immigration advice; capital is at risk, and venture outcomes are highly dispersed.
